Kailo Labs is a nano-tech startup based in Utah that is using Kickstarter to launch an entirely new approach to pain relief. The product is a nanotech-based bio-antenna that, when adhered to the body between the brain and the area experiencing pain, reduces or resolves the pain.
The idea was inadvertently stumbled upon when one of the inventors was laid up with broken ribs. He was working on an antenna while lying down and noticed that when he placed the antenna on his body the pain went away. From there the idea was born.
Now Kailo has raised over $200,000 from its Kickstarter campaign and is circulating testimonials from those who have worn the antenna. Kailo is even touting a 90%+ success rate or customers will get their money back. That success rate is based on customers placing the antenna in the right location and it remains to be seen if this will be a recurring issue.
That being said, Kailo is making the right move in the right sector at the right time. There are a few reasons for optimism about the thus far somewhat mysterious project. Pain relief is a multi-trillion dollar industry that is ripe for disruption. One need look no further than the opioid addiction crisis that is claiming thousands of lives and putting some legacy pharma stalwarts out of business.
At the same time, Kailo is flying way under the radar by only working through crowdfunding sources. The fact that there is ostensibly no drug involved means that the product can escape regulatory scrutiny, but only up to a certain point. Eventually, there will need to be some kind of accounting for whether the product works, even if it is only in the form of more detailed and abundant anecdotal evidence. However, if the product somehow proves to be unsafe (as opioids have) then expect the bottom to fall out quickly.
The biomedical space continues to wait for a dominant player to leverage tech in order to bring seismic reform to an area where trillions are spent every year. Watch Kailo Labs to see if their non-medicine approach becomes that disruption.